Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

AbCellera Biologics Inc. ABCL

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
2.68
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 — — 3 — — 1 — — 4 —
Sell — — — — — — — — — — — —
Insider Ownership
17.01%

Capital & Financial Ratios

Market Cap
4,200.00
Revenue
66.17
Net Income
(164.66)
Free Cash Flow
(119.67)
Net Debt
(565.10)
Current Ratio
12.77
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
58.32
P/B ratio
4.31
Past 5Y EPS Growth
(107.74%)
This Y EPS Growth
(33.82%)
Next Y EPS Growth
(9.30%)
Next 5Y EPS Growth
(18.92%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 785.59 650.61 558.83 565.10
Receivables 30.59 33.62 58.29 18.60
Inventory — — — —
Other 55.81 67.14 111.11 95.53
871.99 751.37 728.23 679.23
2023 2024 2025 Q'26
Payables 49.58 55.00 50.78 32.48
ST’ Debt — — — —
Other — — — —
119.01 76.61 64.31 53.19
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 8.32 4.05 — —
—
’25 4.24 17.08 8.96 44.85
75.13
’24 9.95 7.32 6.51 5.05
28.83
’23 12.19 10.06 6.60 9.18
38.03
’22 316.58 45.92 101.38 21.54
485.42
’21 202.74 27.64 5.51 139.31
375.20
’20 4.66 11.23 9.36 207.91
233.16
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (33.52) 25.92 — —
—
’25 (11.55) (32.40) (52.59) (34.74)
(131.29)
’24 (41.71) (29.97) (28.88) (8.00)
(108.56)
’23 (44.06) 19.90 (0.11) (19.61)
(43.88)
’22 100.22 273.02 (126.79) 30.91
277.36
’21 109.55 157.68 (5.93) (16.71)
244.58
’20 (0.76) 25.98 (3.80) 1.28
22.69
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (37.35) 23.79 — —
—
’25 (22.19) (45.77) (61.52) (44.59)
(174.07)
’24 (65.85) (50.08) (47.40) (23.63)
(186.95)
’23 (59.05) (7.30) (21.00) (34.60)
(121.38)
’22 85.72 241.69 (141.30) 18.58
204.70
’21 105.90 120.88 (14.51) (26.14)
186.13
’20 (6.35) 22.27 (7.69) (0.22)
8.02
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.14) (0.18) — —
—
’25 (0.15) (0.12) (0.19) (0.03)
(0.49)
’24 (0.14) (0.13) (0.17) (0.11)
(0.55)
’23 (0.14) (0.11) (0.10) (0.17)
(0.51)
’22 0.54 (0.02) 0.08 (0.10)
0.50
’21 0.37 (0.01) (0.08) 0.19
0.48
’20 — 0.03 (0.02) 0.43
0.45

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡ 5.42 3.87 2.34 1.89 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 14.97 11.38 6.06 6.52 — — —
High Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 495 586 596 562 — — —
Employees
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.98 0.06 0.05 0.13 — — —
Revenue/Emp
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 485.42 38.03 28.83 75.13 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 239.10 (174.03) (200.39) (177.59) — — —
EBT
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 49.26% (457.67%) (695.02%) (236.39%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 158.52 (146.40) (162.86) (146.41) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.10 30.89 97.00 28.82 — — —
Depreciation
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.70 0.13 0.10 0.25 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 0.56 (0.51) (0.55) (0.49) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.97 (0.15) (0.37) (0.44) ‡‡‡‡‡ — —
Cash Flow/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.25) (0.27) (0.27) (0.14) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.72 (0.42) (0.64) (0.58) — — —
Free CF/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.33 3.99 3.59 3.24 — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 285.06 289.17 294.33 298.71 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 16.95 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.57 43.57 29.91 13.60 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.19 1.44 0.82 1.06 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.87 25.05 10.15 7.24 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.17 (7.68) (1.54) (3.07) — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 277.36 (43.88) (108.56) (131.29) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (72.66) (77.51) (78.40) (42.77) — — —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 204.70 (121.38) (186.95) (174.07) ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 907.17 752.97 674.76 663.93 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.00 — — — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (828.48) (785.58) (650.61) (558.83) — — —
Net Debt
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,233.28 1,152.32 1,056.08 966.90 — — —
Sh' Equity
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.09% (9.67%) (11.43%) (10.78%) — — —
ROA
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.43% (40.43%) (48.52%) (33.25%) — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.03% (12.27%) (14.75%) (14.47%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

AbCellera Biologics (ABCL) rode the COVID wave to glory, exploding from $11.6 million in 2019 revenue to a $485 million peak in 2022 via high-margin antibody deals like Eli Lilly’s bamlanivimab, with revenue per employee hitting $1.13 million and gross margins locked at 100%. But the post-pandemic cliff was savage: 92% revenue plunge to $38 million in 2023, then 24% more to $28.8 million in 2024, dragging the stock down over 95% from $72 highs to $2.34 lows—a brutal biotech derating exposing milestone dependency and pipeline risks.

Profits flipped from $239 million EBT in 2022 to deepening losses (-$200 million in 2024), with cash burn accelerating, shares diluting 95%, and ROIC cratering to -48%. Yet, a fortress balance sheet shines through: $650 million net cash, minimal debt, and insider buys totaling $1.1 million at troughs—no sells in sight—screaming undervaluation at 0.8x PB and forward EV/Sales compressing to 11.7x by 2027.

Analysts eye revival with 26% revenue growth in 2025 ramping to 67% in 2026, driven by oncology assets like ABCL635 and new partnerships, implying 210% mean stock upside (up to 420%). For contrarians, ABCL’s cash hoard funds the burn while betting on AI-platform scalability—but execution slips could torch it all. Dive deeper for the full risk-reward dissection.

Read full commentary →

AbCellera Biologics Inc. (ABCL) Latest News

News by impact score

Fine-tune

16 Sep

3 , 4:05 PM
AbCellera Biologics will present Phase 2 data for ABCL635 at the IMS World Congress on Menopause 2026. Phase 2 data presentation signals pipeline progress in a new therapeutic area with potential to influence investor views.

15 Aug

4 , 9:09 PM
AbCellera (ABCL) shares surge 64% after its drug candidate is positioned for a large market opportunity. Drug candidate market potential triggers major stock gains and signals strong future revenue prospects.

14 Aug

4 , 6:53 PM
AbCellera Biologics enters deal with Vertex Pharmaceuticals that may elevate its TCE platform to breakthrough status. Partnership with Vertex represents major strategic move likely to advance AbCellera's TCE platform and alter its trajectory.

13 Aug

3 , 12:05 AM
AbCellera Biologics priced an oversubscribed $200 million public offering of common shares and pre-funded warrants. The $200 million raise strengthens cash reserves while diluting shareholders.

12 Aug

4 , 3:10 AM
AbCellera Biologics shares surge 60.3% on strong Phase 2 data for menopause drug ABCL635. Strong Phase 2 menopause data for ABCL635 drives major stock gains and signals significant pipeline progress.

4 , 2:14 AM
AbCellera Biologics stock fair value raised after positive clinical data release and new partnership deal with Jazz. Clinical data and Jazz deal represent major strategic progress likely to shift company trajectory and investor views.

3 transcript www.fool.com, 8:31 PM
AbCellera Biologics Inc. held its Q2 2026 earnings call covering quarterly financial results, operational updates, and business outlook. Earnings call delivers financial results and outlook that can shift near-term investor views on ABCL performance.

11 Aug

4 , 11:13 AM
AbCellera Biologics reports positive Phase 2 data for its first pipeline candidate, marking an initial clinical success. Positive Phase 2 results deliver AbCellera its first pipeline milestone and can materially lift valuation and development momentum.

3 , 5:11 PM
AbCellera Biologics (ABCL) stock could be 33% overvalued following ABCL635 Phase 2 results. ABCL635 Phase 2 data prompts valuation reassessment with moderate effect on ABCL stock trajectory.

3 , 4:01 PM
AbCellera Biologics Inc. proposes a public offering of common stock and pre-funded warrants. Offering raises capital for operations while diluting existing shares and pressuring near-term stock price.

10 Aug

4 , 5:40 PM
AbCellera Biologics stock surges 44% after hot flash treatment advances growth outlook. Hot flash treatment success signals major growth potential for AbCellera.

4 , 12:15 PM
AbCellera Biologics Inc. stock rose as much as 41% on positive trial results for its hot-flash drug. Positive hot-flash drug trial results triggered a 41% stock surge, signaling major upside for AbCellera revenue and positioning.

4 , 12:05 PM
AbCellera Biologics stock surged 33% after positive results from a menopause treatment trial. Positive menopause trial results triggered a 33% stock increase and point to expanded pipeline value.

4 www.marketbeat.com, 9:03 AM
AbCellera Biologics' ABCL-635 cuts menopause hot flashes by 83% in Phase II trial. Positive Phase II results for ABCL-635 in menopause treatment indicate major upside for pipeline value and investor interest.

4 investorshub.advfn.com, 8:45 AM
AbCellera Biologics Inc. (ABCL) shares surged 22% after ABCL635 posted positive Phase 2 results. Positive Phase 2 data for ABCL635 represents a major clinical milestone that can materially advance the pipeline and lift valuation.

4 , 7:00 AM
AbCellera Biologics announces positive top-line Phase 2 results for ABCL635, showing significant reduction in vasomotor symptom frequency and severity with favorable tolerability. Positive Phase 2 data for ABCL635 signals major clinical progress that can drive valuation gains and pipeline momentum.

4 stocktwits.com, 6:52 AM
ABCL stock has gained 100% year-to-date, shifting focus to upcoming data readout for its menopause drug. Menopause drug data has potential to materially alter ABCL's trajectory and investor sentiment.

3 , 7:23 AM
AbCellera Biologics Inc. drug shows potential to treat hot flashes, driving 32% stock gain on positive data. Hot flashes drug news triggered 32% ABCL share price jump with moderate long-term implications.

7 Aug

4 , 4:30 PM
AbCellera Biologics will announce top-line results from the Phase 2 trial of ABCL635 for moderate-to-severe VMS due to menopause on August 10, 2026. Phase 2 results for ABCL635 mark a key clinical milestone that can substantially alter company trajectory and investor views.

6 Aug

4 transcript , 1:01 AM
AbCellera Biologics Inc. showed strong pipeline progress in its Q2 2026 earnings call. Pipeline progress represents major strategic advancement with potential to shift company trajectory.

5 Aug

3 transcript www.marketbeat.com, 6:03 PM
AbCellera Biologics held its Q2 earnings call covering financial results, operational updates, and pipeline progress in antibody discovery. Q2 earnings call supplies financial metrics and guidance that can shift near-term investor sentiment without altering long-term trajectory.

3 , 4:05 PM
AbCellera Biologics Inc. released its Q2 2026 business results. Quarterly results update financial performance and can influence investor sentiment without major strategic shifts.

29 Jul

3 , 7:00 AM
AbCellera Biologics announces collaboration with Vertex to discover multispecific T-cell engagers for autoimmune diseases and other conditions. Vertex partnership advances AbCellera's T-cell engager platform into autoimmune indications with potential milestone revenue.

24 Jun

3 Simply Wall St., 4:09 AM
Jazz Pharmaceuticals expands collaboration with AbCellera Biologics despite Zepzelca trial missing primary goal. Expanded Jazz partnership brings AbCellera added collaboration revenue and platform validation.

23 Jun

4 Insider Monkey, 3:39 PM
Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) announced a collaboration. Collaboration with Jazz Pharmaceuticals signals major partnership likely to boost ABCL pipeline and market position.

18 Jun

4 , 10:29 AM
Jazz Pharmaceuticals partners with AbCellera Biologics to develop next-generation therapies for solid tumors. Partnership expands ABCL oncology pipeline and positions company for major growth in solid tumor market.

17 Jun

4 investorshub.advfn.com, 8:50 AM
Jazz Pharmaceuticals partners with AbCellera on antibody programs for solid tumors. Partnership advances AbCellera antibody programs for solid tumors with potential revenue and validation upside.

4 , 7:00 AM
Jazz Pharmaceuticals and AbCellera announce collaboration to discover next-generation T-cell engaging multispecific antibodies. Collaboration expands AbCellera's platform into new multispecific antibody formats with Jazz Pharmaceuticals, strengthening pipeline and revenue potential.

7 Jun

4 Simply Wall St., 2:11 AM
AbCellera Biologics (ABCL) advances ABCL635 program and posts strong Q1 results, prompting updated valuation analysis. ABCL635 progress plus strong Q1 results point to major positive effects on future performance and investor sentiment.

6 Jun

4 Simply Wall St., 8:18 PM
AbCellera Biologics shifts strategy toward proprietary drugs, centering attention on ABCL635 development and corporate governance matters. Strategic move into proprietary drugs signals major business model change with potential to reshape long-term trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us